New bladder cancer cocktail aims to avoid surgery
NCT ID NCT01495676
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tested whether adding gemcitabine to standard cisplatin and radiation could help people with muscle-invasive bladder cancer keep their bladder. About 69 patients were enrolled, but the trial was stopped early. The goal was to see if the combination improved disease-free survival compared to radiation and cisplatin alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRLC GF Leclerc
Dijon, 21000, France
-
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, 34000, France
-
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54511, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Francois Baclesse
Caen, 14000, France
-
Centre azuréen de Cancérologie
Mougins, 06250, France
-
Clinique Patseur
Toulouse, 31300, France
-
HEGP
Paris, 75015, France
-
Hopital Henri Mondor
Créteil, 94010, France
-
Hopital saint Louis
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42705, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine and cisplatin
What this could lead to
If successful, this could offer a bladder-sparing treatment option for muscle-invasive bladder cancer, avoiding radical surgery.
What could go wrong
This trial was terminated early with only 69 participants, so results are limited. The combination may not improve outcomes over standard chemoradiation and could increase side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.